![Govindji Thakershi Hathi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Govindji Thakershi Hathi
Gründer bei Gowrie Laxmico Ltd.
Ursprung des Netzwerks ersten Grades von Govindji Thakershi Hathi
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Laxmi BNS Holdings Ltd.
![]() Laxmi BNS Holdings Ltd. Drugstore ChainsRetail Trade Founded in 2010, Laxmi BNS Holdings Ltd. is a pharmaceutical distribution and British sales company. The company is based in Ruislip, UK.
2
| Subsidiary | Drugstore Chains | 2 |
Gowrie Laxmico Ltd.
![]() Gowrie Laxmico Ltd. Medical DistributorsDistribution Services Gowrie Laxmico Ltd. distributes pharmaceutical products. The company was founded on October 8, 1997 and is headquartered in Middlesex, the United Kingdom.
2
| Private Company | Medical Distributors | 2 |
Laxmico Ltd.
![]() Laxmico Ltd. Medical DistributorsDistribution Services Part of Gowrie Laxmico Ltd., Laxmico is a wholesaler of pharmaceutical products. The company is based in Ruislip, UK. Laxmico was founded in 2009.
2
| Subsidiary | Medical Distributors | 2 |
Syri Ltd. (United Kingdom)
![]() Syri Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Gowrie Holdings Ltd., Syri Ltd. is a British UK-based company founded in 2010. The company specializes in the development, licensing, manufacture, and marketing of liquid medicines.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Govindji Thakershi Hathi
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Novalgen Ltd.
![]() Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Biotechnology | Director/Board Member |
Statistik
International
Vereinigtes Königreich | 2 |
Sektoral
Health Technology | 2 |
Operativ
Director/Board Member | 9 |
Chief Executive Officer | 1 |
Founder | 1 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Samit Govindji Hathi | 5 |
Alpa Hathi | 4 |
- Börse
- Insiders
- Govindji Thakershi Hathi
- Unternehmensverbindungen